Shusen Wang

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center · ORCID：0000-0003-0139-5780

发表论文 234 篇 · 总被引 6922 次 · h-index 40

代表论文

• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 53)
• ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
• Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial (2025 · Journal of Clinical Oncology · 被引 12)
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial (2025 · Nature Communications · 被引 10)
• Utilization and Advancement of an Electrolyte Containing Mixed Electrolyte Salts in Electrochemical Energy Storage Devices Mainly Based on Lithium-Ion Batteries (2025 · Langmuir · 被引 6)
• Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D). (2025 · Journal of Clinical Oncology · 被引 5)